We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
2
ABT icon
Abbott
ABT
+$10.5M
3
OTLK icon
Outlook Therapeutics
OTLK
+$7.71M
4
BPTH
Bio-Path Holdings Inc
BPTH
+$7.56M
5
SHPG
Shire pic
SHPG
+$5.34M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$22.6M
2
BIIB icon
Biogen
BIIB
+$7.14M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$3.88M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.22M
5
ESRX
Express Scripts Holding Company
ESRX
+$2.84M

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SHPG
51
DELISTED
Shire pic
SHPG
$5.44M 0.28%
+29,550
New +$5.34M
ITCI
52
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.33M 0.28%
1,373
+353
+35% +$12.7K
VRTX icon
53
CALL
Vertex Pharmaceuticals
VRTX
$125B
$5.24M 0.27%
609
+59
+11% +$5.1K
EXPR
54
PUT
DELISTED
Express, Inc.
EXPR
$5.04M 0.26%
+33
New +$11.1K
TEVA icon
55
PUT
Teva Pharmaceuticals
TEVA
$40.9B
$5.02M 0.26%
+1,000
New +$53.2K
FOLD
56
CALL
DELISTED
Amicus Therapeutics
FOLD
$4.36M 0.23%
7,992
+5,587
+232% +$39.1K
PRTK
57
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.26M 0.22%
305,964
+113,642
+59% +$1.67M
KITE
58
CALL
DELISTED
Kite Pharma, Inc.
KITE
$4.25M 0.22%
851
+246
+41% +$12.1K
DVAX
59
DELISTED
Dynavax Technologies
DVAX
$4.24M 0.22%
290,505
+70,505
+32% +$1.2M
GBT
60
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.21M 0.22%
254,029
+117,029
+85% +$2.36M
ELDN icon
61
Eledon Pharmaceuticals
ELDN
$267M
$4.13M 0.22%
4,625
-389
-8% -$429K
PSTV icon
62
Plus Therapeutics
PSTV
$25.3M
$4.11M 0.21%
10
+7
+233% +$4.18M
ABUS icon
63
Arbutus Biopharma
ABUS
$875M
$4.09M 0.21%
1,176,031
-21,307
-2% -$90.2K
CEMP
64
PUT
DELISTED
Cempra, Inc.
CEMP
$3.86M 0.2%
2,340
+1,668
+248% +$29.4K
CVM icon
65
CEL-SCI Corp
CVM
$21M
$3.75M 0.2%
+10,885
New +$4.28M
NBIX icon
66
CALL
Neurocrine Biosciences
NBIX
$18.3B
$3.69M 0.19%
813
+448
+123% +$20.6K
HZNP
67
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.63M 0.19%
2,205
+1,297
+143% +$21K
EIGR
68
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.47M 0.18%
5,842
-2,813
-33% -$1.71M
LUMO
69
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.46M 0.18%
641
+435
+211% +$53.9K
ALNY icon
70
PUT
Alnylam Pharmaceuticals
ALNY
$38.7B
$3.36M 0.18%
+606
New +$38.2K
NVIV
71
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$3.35M 0.18%
31
+2
+7% +$235K
INDP icon
72
Indaptus Therapeutics
INDP
$237M
$3.35M 0.17%
332
+13
+4% +$117K
RGLS
73
CALL
DELISTED
Regulus Therapeutics
RGLS
$3.34M 0.17%
96
-2
-2% -$1.43K
LJPC
74
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.3M 0.17%
206,131
+93,947
+84% +$1.69M
RGNX icon
75
Regenxbio
RGNX
$622M
$3.29M 0.17%
411,926
+111,597
+37% +$1.24M
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.